Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma
Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
09/20/2021
Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma
Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
|
|
09/20/2021
USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
|
|
09/18/2021
Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma
LUGANO, Switzerland – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the…
|
|
08/25/2021
Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer
August 24, 2021 Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical Centers NEW YORK – Nouscom…
|
|
08/25/2021
Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
|
|
07/29/2021
In Plain English—June 2021 News from ASCO, the American Society of Clinical Oncology
By Kim Margolin, M.D. You might have seen the term ASCO as you’ve scrolled through melanoma websites or research documents…
|
07/23/2021
President’s Letter | July 2021
From the Desk of Samantha Guild I was struck several times this month with the idea that the fight against…
|
07/22/2021
FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin
July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
|
|
07/21/2021
Chad Freitas and the Skiff Sailing Foundation
By Alicia Rowell, Vice President It was 1986. Chad Freitas was six years old, and he and his dad drove…
|
07/15/2021
The Psychological Well-Being of Skin Cancer Patients
By Alicia Rowell, Vice President With a mom who is a professor of Research Methods in Applied Psychology at the…
Recent Posts
Apr. 16, 2024
Navigating the Journey Together – Conversations with Melanoma Caregivers
Apr. 12, 2024
May is Brain Tumor Awareness Month
Apr. 11, 2024
President’s Letter | April 2024
Apr. 11, 2024
Celebrating a Milestone: 20 Years of the Dallas Steps Against Melanoma Walk
Apr. 11, 2024